CN108602866A - 通过使用cd-rap前体蛋白改善cd-rap制备过程中的表达和折叠 - Google Patents

通过使用cd-rap前体蛋白改善cd-rap制备过程中的表达和折叠 Download PDF

Info

Publication number
CN108602866A
CN108602866A CN201680066638.2A CN201680066638A CN108602866A CN 108602866 A CN108602866 A CN 108602866A CN 201680066638 A CN201680066638 A CN 201680066638A CN 108602866 A CN108602866 A CN 108602866A
Authority
CN
China
Prior art keywords
rap
composition
protein
cartilage
buffer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680066638.2A
Other languages
English (en)
Chinese (zh)
Inventor
伊莎贝尔·舍特勒
尤迪特·斯托姆梅斯
保罗·哈伯曼
贝恩德·亚诺哈
乌尔苏拉·施蒂尔格
埃卡特·巴特尼克
福尔克尔·耶斯克
约阿希姆·扎斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Pharmaceuticals LLC
Original Assignee
Life Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Life Pharmaceuticals LLC filed Critical Life Pharmaceuticals LLC
Publication of CN108602866A publication Critical patent/CN108602866A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680066638.2A 2015-09-18 2016-09-16 通过使用cd-rap前体蛋白改善cd-rap制备过程中的表达和折叠 Pending CN108602866A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15306458.9 2015-09-18
EP15306458 2015-09-18
EP15306457 2015-09-18
EP15306457.1 2015-09-18
EP15306950 2015-12-07
EP15306950.5 2015-12-07
PCT/EP2016/071947 WO2017046314A2 (en) 2015-09-18 2016-09-16 Improvement of expression and folding in the manufacturing process of cd-rap by using a cd-rap precursor protein

Publications (1)

Publication Number Publication Date
CN108602866A true CN108602866A (zh) 2018-09-28

Family

ID=57223637

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680066638.2A Pending CN108602866A (zh) 2015-09-18 2016-09-16 通过使用cd-rap前体蛋白改善cd-rap制备过程中的表达和折叠

Country Status (8)

Country Link
US (2) US10660852B2 (enExample)
EP (1) EP3350204A2 (enExample)
JP (1) JP6976254B2 (enExample)
CN (1) CN108602866A (enExample)
AU (2) AU2016321884B2 (enExample)
CA (1) CA2998665A1 (enExample)
TW (1) TW201726712A (enExample)
WO (1) WO2017046314A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108410803A (zh) * 2018-03-28 2018-08-17 南京千年健干细胞基因工程有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN113024675A (zh) * 2020-12-29 2021-06-25 山东第一医科大学(山东省医学科学院) 一种hb-nc4重组蛋白及其制备方法与应用
CN113412329A (zh) * 2019-02-05 2021-09-17 米其林集团总公司 间苯三酚抗性细胞，特别是酵母

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019024509A1 (zh) * 2018-03-16 2019-02-07 共生地球生物科技有限公司 多重pH缓冲配方与蛋白质消化助剂的组合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1359421A (zh) * 1999-06-30 2002-07-17 武田药品工业株式会社 新型多肽及其dna
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
CN101528197A (zh) * 2006-10-06 2009-09-09 Scil技术股份有限公司 药物应用的干燥重建囊泡制剂
WO2011113604A1 (en) * 2010-03-17 2011-09-22 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
CN102869679A (zh) * 2010-04-27 2013-01-09 Scil技术股份有限公司 稳定的水性mia/cd-rap制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
JP4579378B2 (ja) * 1999-06-30 2010-11-10 武田薬品工業株式会社 新規ポリペプチドおよびそのｄｎａ

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1359421A (zh) * 1999-06-30 2002-07-17 武田药品工业株式会社 新型多肽及其dna
EP1604693A1 (en) * 2004-06-09 2005-12-14 Scil Technology GmbH In situ forming scaffold, its manufacturing and use
CN101528197A (zh) * 2006-10-06 2009-09-09 Scil技术股份有限公司 药物应用的干燥重建囊泡制剂
WO2011113604A1 (en) * 2010-03-17 2011-09-22 Universität Regensburg Peptides or antibodies which bind to melanoma inhibitory activity (mia) protein
CN102869679A (zh) * 2010-04-27 2013-01-09 Scil技术股份有限公司 稳定的水性mia/cd-rap制剂

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
A. LAOUINI等: "Preparation, Characterization and Applications of Liposomes: State of the Art", 《JOURNAL OF COLLOID SCIENCE AND BIOTECHNOLOGY》 *
ARMIN BLESCH等: "Cloning of a Novel Malignant Melanoma-derived Growth-Regulatory Protein, MIA", 《CANCER RESEARCH》 *
MASAHIRO YONEKAWA等: "Serum cartilage-derived retinoic acid-sensitive protein (CD-RAP) levels in Swarm rat chondrosarcoma", 《JOURNAL OF ORTHOPAEDIC RESEARCH》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108410803A (zh) * 2018-03-28 2018-08-17 南京千年健干细胞基因工程有限公司 一种诱导脂肪干细胞成软骨分化的培养方法和培养液
CN113412329A (zh) * 2019-02-05 2021-09-17 米其林集团总公司 间苯三酚抗性细胞，特别是酵母
CN113412329B (zh) * 2019-02-05 2024-03-01 米其林集团总公司 间苯三酚抗性细胞，特别是酵母
CN113024675A (zh) * 2020-12-29 2021-06-25 山东第一医科大学(山东省医学科学院) 一种hb-nc4重组蛋白及其制备方法与应用

Also Published As

Publication number Publication date
US10660852B2 (en) 2020-05-26
AU2016321884B2 (en) 2021-01-07
WO2017046314A3 (en) 2017-05-26
AU2021202110A1 (en) 2021-05-06
JP6976254B2 (ja) 2021-12-08
TW201726712A (zh) 2017-08-01
US20190046442A1 (en) 2019-02-14
AU2016321884A1 (en) 2018-04-12
US20200268663A1 (en) 2020-08-27
WO2017046314A2 (en) 2017-03-23
EP3350204A2 (en) 2018-07-25
JP2018527030A (ja) 2018-09-20
CA2998665A1 (en) 2017-03-23

Similar Documents

Publication Publication Date Title
AU2021202110A1 (en) Improvement of expression and folding in the manufacturing process of CD-RAP by using a CD-RAP precursor protein
US8710013B2 (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
ES2243018T3 (es) Composiciones y metodos de proteinas erizo modificadas hidrofobamente.
JP5989641B2 (ja) リポタンパク質製剤及びその製造方法
US10646431B2 (en) PH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
JP4387101B2 (ja) 糖尿病性網膜症の予防または処置のための網膜細胞アポトーシス抑制剤の使用
JP2020511459A (ja) 軟骨ホーミングペプチドコンジュゲート及びその使用方法
JP2007269778A (ja) 黄斑変性症及び関連眼状態の治療方法
CA3112416A1 (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
CN109925507A (zh) 一种预防或治疗骨关节炎的方法和药物
EP4013876A1 (en) Extracellular vesicle-nlrp3 antagonist
CN102666845B (zh) 磷酸酶和张力蛋白同系物(pten)抑制剂组合物,用途以及方法
JP2009528339A (ja) ペプチド及びその使用
Malishev et al. Bacoside-A, an anti-amyloid natural substance, inhibits membrane disruption by the amyloidogenic determinant of prion protein through accelerating fibril formation
WO2014194428A1 (en) Targeted heparan sulfatase compounds
JP2008510476A (ja) 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
JP2007513881A (ja) Ｘｉ因子の治療学的使用
Zhang et al. Dexamethasone palmitate encapsulated in palmitic acid modified human serum albumin nanoparticles for the treatment of rheumatoid arthritis
WO2018045258A1 (en) TREATMENT OF TNF-alpha CYTOTOXICITY
JPWO2017222042A1 (ja) 眼用医薬組成物
Armbrust The role of meprin β for the pathogenesis of Alzheimer's disease
US20200289416A1 (en) Drug delivery vehicles for atherosclerosis nanomedicine
US20150133367A1 (en) Novel Alpha-Helical Peptidomimetic Inhibitors And Methods Using Same
EP4562156A2 (en) Extracellular vesicle-aso constructs targeting cebp/beta
Checler et al. ERK1-independent α-secretase cut of β-amyloid precursor protein via M1 muscarinic receptors and PKCα/ε☆

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180928